4/18 China Flip Flops On Drug Price Control (Kinda Sorta)
- Drugmakers stopped making certain drugs when they couldn't make money off them
- Poster child was Tapazole; nationwide shortage when Commies set prices too low
China backs away from price controls on basic drugs
will loosen price controls on a list of "commonly used low-cost medicines", allowing pharmaceutical companies to set prices as long as the daily cost of taking the drug "remains in a certain range"
pharmaceutical companies had told Reuters they were unwilling to continue supplying loss-making products
"We stopped producing in June 2012 because the price was too low
4/18 FDA Cracks Down On Opiate Labeling; No More Moderate Pain
- Black box reminds docs when, when not ; admits it's only a recommendation, docs have final say
FDA wants stronger warning labels for long-acting opioids
requiring labels of all long-acting opioids to say they should be used strictly for patients in severe pain
Currently, the labels indicate they are appropriate for patients with moderate and severe pain
DA has acknowledged the agency really has no ability to ensure that doctors actually restrict their prescriptions to patients with severe pain
4/18 Study: Derms Are Suckers For Drug Samples
- Claims sample docs patients spend $465 versus $200 for no-sample docs
Free samples of prescription drugs are costly to patients, study says
$6.3 billion worth of free samples in 2011
25% of their [dermotologist] prescriptions came with a free sample
79% of acne prescriptions in private practices were for name-brand or branded generic drugs, compared with 17% of prescriptions written by the academic dermatologists
Editor's Note: Flawed methodology; authors fail to make the case that samples were the causative effect. Academic docs in general write more generics than private practice docs; was it the really samples that made the difference? Maybe it was another factor. Is it realistic to compare the prescribing habits of a Veterans Admin dermatologist to a 5th avenue dermatologist? Read the article for yourself. Article talks about the "harms of samples". Really? Really? JAMA is anti-pharma. In general, JAMA publishes negative articles regarding samples, sales reps, branded drugs, coupons, etc, yet they cheerfully accept millions of dollars from drug companies for advertising. They never misses a chance to malign the industry; this is no exception.
4/18 Diovan Quirk: Patent Expired, Price Increased,
Branded Product Still Going Strong
- Legal loophole empowers Novartis to charge 37% more than before patent expired
The Law of Gravity Isn't Working for This Off-Patent Drug
safety concerns over Ranbaxy's factories in India have kept the company from selling its Diovan version. Since other drugmakers can't market their own generics until Ranbaxy's pill has been on sale for 180 days, Novartis continues to be the only seller of the heart pill in the U.S.--at a price that's 37 percent higher than what the company charged when the medicine was under patent
4/18 Glaxo: 5 Bribery Scandals Later, Hypes Strategy To Take Incentives Away From Salesmen, Docs
GSK, facing bribery claims, battles to build new sales model
aims to become the first in the industry to stop paying outside doctors to promote its products, end payments for medics to attend conferences and delink incentives for sales representatives from individual sales targets
insiders - say GSK's unilateral move risks putting it at a marketing disadvantage, particularly in emerging markets
intends to make much greater use of digital technologies, such as webcasts and webinars
4/17 Fast Takes
Mylan Launches First Generic ORTHO EVRA® Patch
Mylan Press Release
Reckitt leans towards pharmaceuticals spin-off
Antidepressant Use in Pregnancy Tied to Autism Risk
IMPAX Launches Authorized Generic RENVELA®
Can Once Daily GLP-1 Lyxumia Be The Next Major Growth Driver For Sanofi?
Ex-Sanofi Executive Gets 16 Months for Insider Trading
4/17 Stolen Herceptin, Fake Herceptin Turns Up On Open Market
- Thought to be stolen from hospitals in Italy
Stolen Vials of Cancer Drug Reintroduced as Counterfeits
Vials of the cancer drug Herceptin probably stolen in Italy have been tampered with and reintroduced into the medicine supply chain, the European Medicines Agency said.
didn't say how much of the drug was stolen, or where and when it was taken.
4/17 Primary Care Docs: 16 Mins Per Patient, Other Interesting Stats
Survey finds pay doesn't make doctors happy
55% said they spent 16 minutes at most ...42% pushed past the 17-mark
72% said they "regularly or occasionally discuss the cost of treatment
orthopedists are the highest paid physicians ($413,000 per year
cardiologists who reported $351,000
Related: If Being A Doctor Is So Horrible, Why Are Med School Applications At A Record High?
4/17 30,000 Foot View: Side Effect Profile, Efficacy of Diabetes Drugs
- Free Report; Data mining of FDA adverse data reporting database for branded diabetes drugs
- Goes so far as to name the safest drug in each class
The Comparative Safety of Type 2 Diabetes Medications:
SLGT2 inhibitors are, as expected, associated with elevated urinary infection risks but may also be linked to more serious events
GLP-1 and DPP-4 inhibitors (especially sitagliptin) have elevated associations with pancreatitis and pancreatic cancer, but neither class appears to have strong links to presumed renal and hepatic complications
Editor's Note: FREE Download; sign-up required; 23 pages; 7,500 words; many statistics; suggested reading if you market a type 2 diabetes product; has relative risk data for all drugs, A1C lowering potential of all NIDDM meds; not copy approved, do not use for promotion.
See Also: New report finds Bydureon safest of new class of diabetes drugs
Janumet and Januvia from Merck Tradjenta from Boehringer Ingelheim and Eli Lilly ($LLY), and Nesina from Takeda, may be linked to more serious side effects than has generally been believed. It found that Nesina raised the most concern
4/17 Glaxo New Once Weekly GLP1: Not Gonna Be Easy
Newly minted GlaxoSmithKline diabetes drug faces formidable foes in GLP-1 market
data doesn't give it an efficacy edge on Victoza, so its once-weekly dosing--compared with the Novo drug's once-daily schedule--is Glaxo's best talking point. But Bydureon is a once-weekly drug, too
4/17 Cancer Drugs: Beginning Of End Of Blank Check Mentality?
Cancer Doctors Plan to Compare Value of Expensive Drugs
world's largest organization of cancer doctors plans to rate the cost effectiveness of expensive oncology drugs, and will urge physicians to use the ratings to discuss the costs with their patients.
framework for a scoring system that will give doctors and patients options to discuss in determining how to proceed with care
4/17 Former Novo Drug Rep, Murderer To Get New Trial (His 3rd)
- Judge allowed non-kosher evidence that swayed jury
Raleigh Convicted Murderer Jason Young Granted Third Trial
Young did not have charges filed against him for years until investigators said they had gathered enough evidence against him. He first went to trial in 2011 and after a mistrial was declared, he was put on trial again in 2012
judge made an error in the second murder trial when he allowed evidence to be entered into the criminal trial that was from a previous civil lawsuit